SCHEMBL6489509

SCHEMBL6489509

Cc1cc(C(=O)O)cn2ccnc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.56
RXFP1 Q9HBX9 1/20 0.39
SPTLC1 O15269 1/20 0.38
SLC22A12 Q96S37 3/20 0.37
XDH P47989 1/20 0.37
SYK P43405 2/20 0.36
TNKS O95271 1/20 0.36
MYC P01106 1/20 0.36
ESR1 P03372 1/20 0.36
ALOX15 P16050 1/20 0.36
PTPN7 P35236 1/20 0.36
HSD17B10 Q99714 1/20 0.36
JMJD6 Q6NYC1 1/20 0.36
HDAC6 Q9UBN7 2/20 0.35
ADORA3 P0DMS8 2/20 0.35
TMIGD3 P0DMS9 2/20 0.35
ADH5 P11766 1/20 0.35
NR4A1 P22736 1/20 0.35
NR4A2 P43354 1/20 0.35
KDM5A P29375 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23029791 0.85 L3MBTL1 (0.54) L3MBTL1SPTLC1SLC22A12SYKTNKS
SCHEMBL23029808 0.83 L3MBTL1 (0.51) L3MBTL1SPTLC1SLC22A12SYKTNKS
SCHEMBL25149587 0.83 L3MBTL1 (0.51) L3MBTL1RXFP1SYKALOX15JMJD6
SCHEMBL23029794 0.83 L3MBTL1 (0.51) L3MBTL1SYKHDAC6ADORA3TMIGD3
SCHEMBL29413476 0.80 MAOB (0.40) L3MBTL1SPTLC1SLC22A12XDHADORA3
SCHEMBL25149736 0.80 L3MBTL1 (0.44) L3MBTL1SPTLC1SLC22A12XDHSYK
SCHEMBL12678003 0.78 L3MBTL1 (0.47) L3MBTL1SPTLC1SLC22A12SYKHDAC6
SCHEMBL454081 0.78 SPTLC1 (0.53) L3MBTL1SPTLC1SLC22A12XDHTNKS
SCHEMBL16739621 0.78 ADH5 (0.40) L3MBTL1SPTLC1SLC22A12XDHSYK
SCHEMBL2260742 0.74 L3MBTL1 (0.67) L3MBTL1TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118043321-A Imidazo [1,2-a ] pyridine derivatives 先正达农作物保护股份公司 2024-05-14 CN disclosed
US-6858613-B2 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PFIZER INC. (US) 2005-02-22 US disclosed
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236264-A1 Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease NAT1, CYP11B1, COASY L3MBTL1 3266/4885RXFP1 2951/4885SPTLC1 1193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.